Our applications for gut research

Helping to reveal the far-reaching effects of gut microbiome with metabolomics

Our applications for gut research

Helping to reveal the far-reaching effects of gut microbiome with metabolomics

Metabolomics as a powerful tool for gut research

Metabolomics supports understanding the molecular mechanisms and functions associated with gut microbiota by revealing host-microbiome associations. Detailed metabolic profiling in blood and urine is a powerful tool for discoveries in microbiome associations, providing a quantified​ overview of host health status and supplying indications of future disease risks.

Explore the relationship between host and gut microbiome

Gut researchers are facing several challenges where metabolomics can be of help. As the health effects of the gut microbiota are systemic and may develop over several years, showing causality is complicated in human studies. However, metabolic profiling enables risk estimation for several disease conditions and discoveries in associations between gut condition, gut microbes, nutrition and human health.

Some of the mechanisms of how gut microbes affect health have already been identified. Healthy gut lining with rich microbial diversity appear to have a protective effect against numerous diseases, whereas impaired gut epithelium and aberrant gut microbiome composition are associated with metabolic and autoimmune diseases, and mental disorders. Enhanced leakage of pro-inflammatory components of bacterial cell wall from the gut to host circulation feeds low-grade inflammation and sways the balance of host metabolism with severe and long-lasting effects on health and disease risk. Such effects are reflected in host lipid, sugar and inflammation related metabolites and are quantifiable by metabolomics.

Explore the relationship between host and gut microbiome

Gut researchers are facing several challenges where metabolomics can be of help. As the health effects of the gut microbiota are systemic and may develop over several years, showing causality is complicated in human studies. However, metabolic profiling enables risk estimation for several disease conditions and discoveries in associations between gut condition, gut microbes, nutrition and human health.

Some of the mechanisms of how gut microbes affect health have already been identified. Healthy gut lining with rich microbial diversity appear to have a protective effect against numerous diseases, whereas impaired gut epithelium and aberrant gut microbiome composition are associated with metabolic and autoimmune diseases, and mental disorders. Enhanced leakage of pro-inflammatory components of bacterial cell wall from the gut to host circulation feeds low-grade inflammation and sways the balance of host metabolism with severe and long-lasting effects on health and disease risk. Such effects are reflected in host lipid, sugar and inflammation related metabolites and are quantifiable by metabolomics.

Nightingale’s platform in gut research

Nightingale’s biomarker panel covers a vast range of the main biological pathways and supplies a comprehensive overview of the metabolic health of the human host. In addition, our platform offers the means to simultaneously​ examine several metabolic pathways, including biomarkers like fatty acid acetate and GlycA in blood, as well as TMAO, dimethylamine and lactate in urine. 

Several studies have used Nightingale’s NMR metabolomics platform to explore novel biomarkers for gut diseases and functional gut microbiota research. For instance, a low-grade inflammation marker, glycoprotein acetyls (GlycA), has shown promising evidence as a viable biomarker for inflammatory bowel disease, intestinal permeability and microbial richness. Detailed metabolic profiling in combination with gut microbiota profiling has shed light on the functional crosstalk between gut microbiota and obesity status, as well as type 2 diabetes and cardiovascular disease risk.

Nightingale’s platform in gut research

Nightingale’s biomarker panel covers a vast range of the main biological pathways and supplies a comprehensive overview of the metabolic health of the human host. In addition, our platform offers the means to simultaneously​ examine several metabolic pathways, including biomarkers like fatty acid acetate and GlycA in blood, as well as TMAO, dimethylamine and lactate in urine. 

Several studies have used Nightingale’s NMR metabolomics platform to explore novel biomarkers for gut diseases and functional gut microbiota research. For instance, a low-grade inflammation marker, glycoprotein acetyls (GlycA), has shown promising evidence as a viable biomarker for inflammatory bowel disease, intestinal permeability and microbial richness. Detailed metabolic profiling in combination with gut microbiota profiling has shed light on the functional crosstalk between gut microbiota and obesity status, as well as type 2 diabetes and cardiovascular disease risk.

The next frontiers

Instead of exploring what’s in the gut, the microbiome research community now seeks answers to what is the function of the gut microbiome.  

Inflammatory bowel disease is an example of a chronic disease with quickly increasing prevalence that is on the verge of becoming a serious global health problem in the coming years. There is a crucial need for novel ways to predict, monitor and treat this condition. Nightingale’s metabolic profiling provides an affordable way to gain metabolic insights on the disease progression of inflammatory bowel disease, and can identify metabolic signatures that characterise preclinical symptoms. This knowledge can pave the way for preventive healthcare and distinguish novel therapeutic targets for accurate treatment of inflammatory bowel disease. 

The next frontiers

Instead of exploring what’s in the gut, the microbiome research community now seeks answers to what is the function of the gut microbiome.  

Inflammatory bowel disease is an example of a chronic disease with quickly increasing prevalence that is on the verge of becoming a serious global health problem in the coming years. There is a crucial need for novel ways to predict, monitor and treat this condition. Nightingale’s metabolic profiling provides an affordable way to gain metabolic insights on the disease progression of inflammatory bowel disease, and can identify metabolic signatures that characterise preclinical symptoms. This knowledge can pave the way for preventive healthcare and distinguish novel therapeutic targets for accurate treatment of inflammatory bowel disease. 

Related services

Our blood and urine platforms enable researchers to explore connections how gut affects different aspects of human health.

Contact

Whether you have a question or you would like to ask for an offer, let us know and we'll get back to you very soon.